Molecular-targeted Radiosensitization by Small Fusion Peptides for Prostate Cancer

C. Lin,H. Zhao,Y. Cui

DOI: https://doi.org/10.1016/j.ijrobp.2011.06.296

2011-01-01

Abstract:Radiation therapy is one of the critical treatments for prostate cancer. Tumor specific radiosensitization would increase the treatment outcome and reduce radiation damage to normal tissues. DNA damage signal transducers such as the ATM and ATR kinases play critical roles to initiate the DNA damage response and determine the radiosensitivity by phosphorylating specific serine or threonine residues (SQ or TQ). Of the target proteins, the two effector kinases Chk1 and Chk2 are particularly important because they phosphorylate additional substrates to amplify the signals. To explore novel approaches to molecularly targeted radiosensitization, we characterized small fusion peptides containing the ATM and ATR phosphorylation sequences of Chk1 and Chk2. We synthesized nine small fusion peptides which contain two functional domains: one for internalization (the HIV-TAT sequence) and the other for blocking Chk1 or Chk2 phosphorylation. The fusion peptides include TAT-only, Chk1 peptides TAT-wild-type Serine 317, TAT-wild-type Serine 345, Chk2 peptides TAT-wild-type Threonine-68, TAT-wild-type Threoine-383, TAT-wild-type Threonine 387, and their respective mutants TAT-Chk1 Ser317Ala, TAT-Chk1 Ser345Ala, TAT-Chk2 Thr68Ala, TAT-Chk2 Thr383Ala, TAT-Chk2 Thr387Ala. To characterize the radiosensitization effect of the peptides, we utilized two prostate cancer cell lines (PC-3 and DU-145). Cells were exposed to irradiation (IR) after incubation with either of the peptides. We assessed IR-induced Chk1 and Chk2 activation and phosphorylation using immunoblotting using phospho-specific antibodies. We also investigated effects of the peptides on IR-induced cell cycle checkpoints. Finally we assessed radiosensitivity using the clonogenic survival assay. We found that wild-type peptides of Chk1 and Chk2 can clock ATM and ATR mediated Chk1 and Chk2 phosphorylation/ activation. The mutant peptides did not process any inhibitory effects on the kinases. Treatment with Chk1 or Chk2 peptides resulted in loss of the IR-induced G2/M checkpoint. Cells exposed to the wild-type Chk1 or Chk2 fusion peptides have increased radiosensitivity, with TAT-wild-type Chk2 Threonine-68 the highest Sensitization Enhancement Ratio (2.17). Small inhibitory peptides on Chk1 and Chk2 activation and phosphorylation can be explored to be novel agents for radiosensitization in prostate cancer as well other cancer types.